FLUOXETINE IN THE TREATMENT OF PREMENSTRUAL DYSPHORIA
FLUOXETINE IN THE TREATMENT OF PREMENSTRUAL DYSPHORIA
复制标题
DOI：
10.1056/nejm199506083322301
复制
发表时间：
1995-06-08
影响因子：
158.5
通讯作者：
STREINER, D
中科院分区：
文献类型：
--
作者：
STEINER, M;STEINBERG, S;STREINER, D
背景资料。经前焦虑症具有抑郁和焦虑状态的某些特征，这与5-羟色胺能失调有关。我们评价了氟西汀(选择性抑制5-羟色胺再摄取)治疗经前消化不良的疗效和安全性。这项试验包括持续两个月经周期的单盲安慰剂洗脱期，然后是随机、双盲、安慰剂对照试验，氟西汀剂量为每天20毫克或60毫克，或安慰剂，共6个月经周期。符合当时被称为黄体晚期焦虑症标准的健康女性在加拿大的七所大学附属妇女健康诊所招募。主要的结果测量包括每个周期黄体晚期紧张、易怒和烦躁不安的视觉模拟评分。在参加安慰剂洗涤期的405名女性中，313人随后进入随机研究阶段，持续了6个月经周期，180人完成了研究。视觉模拟评分显示，氟西汀20~60 mg/d组在缓解紧张、易怒、烦躁等症状方面明显优于安慰剂组(P
Background. Premenstrual dysphoria shares certain features with depression and anxiety states, which have been linked to serotonergic dysregulation. We evaluated the efficacy and safety of fluoxetine (which selectively inhibits the reuptake of serotonin) in the treatment of premenstrual dysphoria.Methods. The trial consisted of a single-blind, placebo washout period lasting two menstrual cycles, followed by a randomized, double-blind, placebo-controlled trial of fluoxetine at a dose of either 20 mg or 60 mg per day or placebo for six menstrual cycles. Healthy women meeting criteria for what was then called late-luteal-phase dysphoric disorder were recruited at seven university-affiliate women's health clinics in Canada. The primary outcome measure consisted of visual-analogue scales for tension, irritability, and dysphoria during the late luteal phase of each cycle.Results. Of 405 women enrolled in the placebo washout period, 313 subsequently entered the randomized phase of the study, which lasted six menstrual cycles, and 180 completed it. Fluoxetine at a dose of 20 or 60 mg per day was significantly superior to placebo in reducing symptoms of tension, irritability, and dysphoria, as measured by the visual-analogue scales (P